TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Therapy Development for Methamphetamine Abuse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the University of California, Los Angeles (UCLA) Center for Clinical AIDS Research and Education (CARE) clinic, aged 18-65~2. Willing to give informed consent and comply with study procedures~3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications~4. Diagnosed with current methamphetamine abuse as determined by Mini-International Neuropsychiatric Interview (MINI)~5. Interested in seeking treatment for methamphetamine abuse and in participating in this research project.~Exclusion Criteria:~1. Unwilling to give, or withdrawal of, informed consent~2. Inability to understand nature of study~3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision \[DSM-IV-TR\] criteria for current bipolar disorder or a psychotic disorder)~4. Current suicidal ideation or suicide attempt within the past 3 months~5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.~6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Relationship Between Triglycerides and Fetal Overgrowth in Gestational Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* singleton pregnancy~* diagnosis of GDM between 24-32 weeks~* BMI \>= 30~Exclusion Criteria:~* Conditions known to impact fetal growth.These conditions can develop after study enrollment but cannot be present at enrollment.~* autoimmune conditions treated with medication~* chronic hypertension requiring medication~* preeclampsia~* fetal growth restriction diagnosis~* smoking~* illicit drug use~* major fetal anomalies~* fetal genetic conditions

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pregnancies with GDM and BMI > 30 (Type: None): Pregnancies with GDM diagnosed between 24-32 weeks and BMI \> 30.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who understand and are willing to give informed consent to participate in the trial.~* Adult male and female subjects between 18 years to 65 years of age with a BMI ≥ 27 kg/m2 ≤ 40 kg/m2, inclusively.~* Subjects with established type 2 diabetes mellitus of at least 3 months duration at the time of screening.~* Subjects with an inadequate glycemic control defined by an HbA1c level of ≥ 7.5% and ≥10% at screening.~* Subjects who are on a stable dose of:~  * Metformin (up to 2.55 gm/day or maximum tolerated dose of at least 1 gm/day) and/or~ * Sulfonylurea (glimepiride ≤ 4 mg/day, gliclazide ≤ 160 mg, glibenclamide or glyburide ≤ 10 mg and glipizide ≤ 10 mg), for ≤ 2 months prior to the screening visit.~* Subjects with fasting plasma glucose of ≤14.4 mmol/L (260 mg/dL) and at least 5.5 mmol/L or 100 mg/dL.~Exclusion Criteria:~* Subjects who have type 1 diabetes mellitus, maturity-onset diabetes of the young or any rare form of diabetes. Subjects with hyperglycemia due to secondary causes.~* Subjects who have had more than 4 episodes of severe hypoglycemia in the 6 months prior to screening.~* Subjects with a history of acute diabetic complications~* Subjects who have been treated with insulin (except for use of insulin for short term management of acute conditions), thiazolidinediones, dual proliferator activated receptors agonists, glucagon-like peptide analogues, dipeptidyl peptidase inhibitors or 11bHSD-1 inhibitors in any form, in the 3 months prior to screening.~* Subjects who are receiving systemic glucocorticoids (≥14 days)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- P2202 (Type: ACTIVE_COMPARATOR): Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo
- Placebo (Type: PLACEBO_COMPARATOR): Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Mode of Contraction on Neuromuscular Fatigue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Belong to a defined age group: young (18 to 35 years old inclusive), old (60 to 80 years old inclusive) and very old (81 to 95 years old inclusive),~* Signed written consent form~* Being affiliated to social security~Exclusion Criteria:~* Pathology or surgery resulting in a locomotor disorder, within 6 months prior to the study,~* Chronic neurological, motor or psychological pathologies~* Use of neuro-active substances likely to alter cortico-spinal excitability (hypnotics, antiepileptics, psychotropic drugs, muscle relaxants) for the duration of the study.~* Contraindication to magnetic stimulation:~* Cardiac or respiratory insufficiency.~* Cardiac pacemaker.~* Cardiac valve wear and serious cardiovascular diseases.~* Presence of prosthetic material or ferromagnetic foreign bodies in the head.~* Presence of cochlear implants or ocular prosthetic material.~* History of neurosurgical interventions.~* Neurological diseases that may affect brain structures and cognitive abilities (e.g., intracranial tumour, multiple sclerosis, history of stroke or traumatic brain injury).~* History of comitiality, contralateral knee pathology or pathology of the musculoskeletal system.~* Mini Mental State Examination \< 20

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Young people (Type: EXPERIMENTAL): Men or Women under 35 years old
- Old people (Type: EXPERIMENTAL): Men or Women between 60 and 80 years old
- Very old people (Type: EXPERIMENTAL): Men or Women over 80 years old

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* CDAI \> 220 und \< 450~* Biologika naiv~* CD seit \> 6 Monaten~Exclusion criteria:~* other TNF-Blocker~* Steroids \> 40 mg~* Malignoma in der Anamnesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of age of 18 years or older.~* Have thrombocytopenia or expected to develop thrombocytopenia requiring at least 3 platelet transfusions.~* Woman of child bearing potential must have a negative serum or urine pregnancy test within 72 hours before randomization.~* Subjects must have signed and dated the Informed Consent Form before performing any protocol related procedure.~Exclusion Criteria:~* History of any hypersensitivity reaction to riboflavin or metabolites.~* History of refractoriness to platelet transfusions (defined as 2 successive CCI1hr\<5000) or presence of human leukocyte antigen (HLA) antibodies or positive lymphocytotoxicity or previously documented alloimmunization.~* Previous exposure to PRT-treated platelet concentrates.~* Active bleeding requiring one or more red cells concentrate transfusions (i.e. grade 3 or 4 bleeding according to the WHO bleeding assessment scale in Appendix 1).~* Exposure to an investigational product, within 30 days before randomization.~* Splenomegaly (presence of a palpable spleen whose border could be felt more than 4 cm below the costal margin) or splenectomy.~* History or diagnosis of Immune/Idiopathic Thrombocytopenic Purpura (ITP), Thrombotic Thrombocytopenia Purpura (TTP), or Haemolytic Uremic Syndrome (HUS).~* Use of prohibited medication (see section 5.5).~* Pregnant or lactating females.~* Any medical condition or treatment that would be expected to compromise the effectiveness of a platelet transfusion or that would interfere with an expected platelet count increment.~* Any other medical condition that would compromise the participation of the subject in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirasol first, then Reference (Type: ACTIVE_COMPARATOR): This study arm will receive first a 2-4-day-old Mirasol-treated platelets transfusion and then a reference 2-4-day-old untreated platelets transfusion (Mirasol-Reference sequence).
- Reference first, then Mirasol (Type: ACTIVE_COMPARATOR): This study arm will receive first a reference 2-4-day-old untreated platelets transfusion and then a 2-4-day-old Mirasol-treated platelets transfusion (Reference-Mirasol sequence).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with measurable, histological diagnosis of hepatocellular carcinoma (HCC) and whose disease is not amenable to surgical or regional therapy.~2. Prior allowed therapy:~   * Surgery including hepatic resection~     1. Minimum of 4 weeks since any surgical procedure.~    2. Patients must have adequately recovered from surgery.~  * Regional therapy~     1. Includes transarterial chemoembolization (TACE), drug-eluting bead \[DEB\]-TACE, percutaneous ethanol injection, radiofrequency/cryo ablation, Yttrium-90 radioembolization.~    2. More than 2 weeks must have lapsed from therapy.~    3. There must be an indicator lesion outside the treated area or clear evidence of progression in the treated lesion, not amenable for further local therapies.~    4. Concomitant sorafenib with regional therapy is allowed as long as no evidence of progression on sorafenib.~  * Prior adjuvant sorafenib is allowed, if completed more than 6 months prior to disease recurrence.~3. Adequate hematological, liver and metabolic organ function.~4. Signed informed consent.~Exclusion Criteria:~1. Patients with mixed histology or fibrolamellar variant.~2. Prior systemic therapy for metastatic disease.~3. Uncontrolled hypertension (HTN).~4. Symptomatic heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tivozanib (Type: EXPERIMENTAL): Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging (MRI) in the Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Response

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of loco-regionally advanced (stage III or IV) squamous cell carcinoma of the head and neck (oropharynx, hypopharynx and larynx)~* Age \> 18 years~* No prior surgery, chemotherapy or radiation therapy for head and neck cancer~* Scheduled to receive chemoradiation for definitive therapy~Exclusion Criteria:~* Contraindications to MRI (pacemaker, aneurysm clip, mechanical and/or electrical device or metallic fragment, severe claustrophobia)~* Contraindications to gadolinium~* Severe, active co-morbidity~* Major medical illnesses or psychiatric impairments~* Pregnant or nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Register and DNA Bank of Adult Extra-hospital Sudden Death (Protocol FASTER)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA :~* Inclusion criteria for register :~* Adults ≥ 18 years of age.~* Persons who experienced sudden death defined as follows :cardiovascular arrest of non traumatic origin that occurred unexpectedly within an hour after the start of any prodromes.~* Patients not hospitalized at the time of sudden death.~* Inclusion criteria for DNA bank :~* Case subjects :~* Adults ≥ 18 years of age.~* Persons who experienced sudden death defined as follows :cardiovascular arrest of non traumatic origin that occurred unexpectedly within an hour after the start of any prodromes.~* Patients not hospitalized at the time of sudden death.~* Patients supported clinically by an emergency ambulance service.~* Control subjects :~* Adults ≥ 18 years of age.~* Adults hospitalized in an cardiac intensive care unit.~EXCLUSION CRITERIA :~* Exclusion criteria for register :~* Violent death : criminal, suicidal or accidental.~* Exclusion criteria for DNA bank :~* Case subjects :~* Violent death : criminal, suicidal or accidental.~* Identified cause of death extra-cardiac : neurological cause, hypoxia, pulmonary embolism, aortic rupture or other identified extra-cardiac cause.~* In accordance with Articles L1221-5 L1221-L1221-8 and 8-1 of the Code of Public Health, the categories of persons are excluded from research due to the fact that it can be achieved with an efficiency comparable over another class of people :~* Adult subject to legal protection measure,~* Pregnant woman,~* Parturient,~* Breastfeeding mother,~* Person deprived of liberty,~* Person hospitalised without his consent,~* Person admitted to a medical or socially facility.~* Control subjects :~* History of sudden death,~* Documented history of ventricular fibrillation,~* History of sustained ventricular tachycardia (lasting longer than 30 seconds) documented.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Case subjects (Type: OTHER): None
- Control subjects (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ASTIC Autologous Stem Cell Transplantation for Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria: mandatory~1. Age between 18 and 50 years (Patients aged 50-65 can participate if specially approved by the Trial Steering Committee)~2. Confirmed diagnosis of active Crohn's Disease~3. Unsatisfactory course despite 3 immunosuppressive agents (usually azathioprine, methotrexate and infliximab) in addition to corticosteroids. Patients should have relapsing disease (i.e. \>1 exacerbation/year) despite thiopurines, methotrexate and/or infliximab maintenance therapy or clear demonstration of intolerance / toxicity to these drugs.~4. Impaired function and quality of life, compared to population means, on at least one of the following:~   1. IBDQ (Appendix 6)~  2. European Questionnaire of Life quality (EuroQOL-5D, Appendix 4)~  3. Impaired function on Karnofsky index (Appendix 7)~5. Current problems unsuitable for surgery and patient at risk for developing short bowel syndrome.~6. Informed consent~Inclusion criteria: discretionary~1. Wherever possible, diseased tissue should be accessible endoscopically for objective histological study but in the case of small bowel disease that is extensive but does not extend to duodenum or terminal ileum, participation without endoscopy is allowed.~2. Smokers may enter the study provided they have received intensive counselling about smoking.~3. Add patients with ileostomy/colostomy and patients with short bowel syndrome~Exclusion Criteria:~1. Pregnancy or unwillingness to use adequate contraception during the study~2. Concomitant severe disease~3. Diarrhoea due to short small or large bowel~4. Infection or risk thereof~5. Significant malnutrition: Body Mass Index (BMI) ≤18, serum albumin \<20 g/l~6. Previous poor compliance~7. Concurrent enrolment in any other protocol using an investigational drug or hematopoietic growth factor up to four weeks before study entry.~8. Lack of funding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplant Arm (Type: EXPERIMENTAL): Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
- Delayed Transplant (Type: EXPERIMENTAL): Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven metastatic breast cancer Adequate peripheral blood stem cells harvested and stored~PATIENT CHARACTERISTICS: Age: 21-65 Sex: Female Performance status: 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 1.5 mg/dL SGOT and SGPT normal Renal: Creatinine less than 1.5 mg/dL Cardiovascular: Ejection fraction of at least 50% No symptomatic coronary artery disease Pulmonary: FEV1 and DLCO greater than 50% of predicted Other: Not pregnant Not HIV positive Not hepatitis B surface antigen positive No uncontrolled infection No other prior malignancy within 5 years except: Curatively treated in situ adenocarcinoma of the cervix Curatively treated nonmelanoma skin cancer~PRIOR CONCURRENT THERAPY: Recovered from toxic effects of prior therapy Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for metastatic disease Prior adjuvant chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy for metastatic disease Surgery: Not specified

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.~* Diagnosis of MS, including Clinically Isolated Syndrome (CIS)~* Ability to understand the audio and visual instructions for the test modules~* Visual function, based on the investigator's clinical judgement, that does not preclude an ability to interact with the MSPT.~Exclusion Criteria:~* Unable or unwilling to provide informed consent.~* Patients under 18 years of age will be excluded.~* Other unspecified reasons that, in the opinion of the Sponsor-Investigator, make the patient unsuitable for participation in the demonstration project. A patient only needs to complete the assessments deemed appropriate by the Sponsor-Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MS patients including CIS (Type: None): Patients with a diagnosis of MS, including Clinically Isolated Syndrome (CIS), who have the ability to understand the audio and visual instructions for the MSPT modules and whose visual function that does not preclude an ability to see the screen of the MSPT tool.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility